Immunology of chronic myeloid leukemia: Current concepts and future goals

Expert Review of Clinical Immunology

Volumn 11, Issue 4, 2015, Pages 511-522

  Vonka, Vladimír ^a   Petráčková, Martina ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

Author keywords

bcr abl; cancer vaccines; CML; immunology; immunotherapy; LAAs; tyrosine kinase inhibitors

Indexed keywords

BCR ABL PROTEIN; LEUKEMIA ANTIGEN; TUMOR CELL VACCINE; CANCER VACCINE; PROTEIN KINASE INHIBITOR;

ADAPTIVE IMMUNITY; ADOPTIVE IMMUNOTHERAPY; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CELLULAR IMMUNITY; CHRONIC MYELOID LEUKEMIA; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNE SYSTEM; NONHUMAN; REVIEW; TUMOR CELL; ANIMAL; CLINICAL TRIAL (TOPIC); IMMUNOLOGY; IMMUNOTHERAPY; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; REMISSION;

ANIMALS; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTHERAPY; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PROTEIN KINASE INHIBITORS; REMISSION INDUCTION;

EID: 84924933672     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/1744666X.2015.1019474     Document Type: Review

References (85)

1. Rohrbacher M, Hasford J. Epidemiology of chronic myeloid leukaemia (CML). Best Pract Res Clin Haematol 2009;22:295-302
2. Huang X, Cortes J, Kantarjian H. Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer 2012;118:3123-7
3. Wagner WM, Ouyang Q, Pawelec G. The abl/bcr gene product as a novel leukemia-specific antigen: peptides spanning the fusion region of abl/bcr can be recognized by both CD4+ and CD8+T lymphocytes. Cancer Immunol Immunother 2003;52:89-96
4. Zheng X, Oancea C, Henschler R, et al. Reciprocal t(9;22) ABL/BCR fusion proteins: leukemogenic potential and effects on B cell commitment. PLoS One 2009;4: e7661
5. Oehler VG, Radich JP, Storer B, et al. Randomized trial of allogeneic related bone marrow transplantation versus peripheral blood stem cell transplantation for chronic myeloid leukemia. Biol Blood Marrow Transplant 2005;11:85-92
6. Radich J. Stem cell transplant for chronic myeloid leukemia in the imatinib era. Semin Hematol 2010;47:354-61
7. Smith AG, Painter D, Howell DA, et al. Determinants of survival in patients with chronic myeloid leukaemia treated in the new era of oral therapy: findings from a UK population-based patient cohort. BMJ Open 2014;4:e004266
8. le Coutre P, Tassi E, Varella-Garcia M, et al. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 2000;95: 1758-66
9. Azam M, Daley GQ. Anticipating clinical resistance to target-directed agents: the BCR-ABL paradigm. Mol Diagn Ther 2006;10:67-76
10. Ross DM, Branford S, Seymour JF, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 2013;122:515-22
11. Vonka V. Immunotherapy of chronic myeloid leukemia: present state and future prospects. Immunotherapy 2010;2:227-41
12. Pinilla-Ibarz J, Shah B, Dubovsky JA. The biological basis for immunotherapy in patients with chronic myelogenous leukemia. Cancer Contr 2009;16:141-52
13. Ilander M, Hekim C, Mustjoki S. Immunology and immunotherapy of chronic myeloid leukemia. Curr Hematol Malig Rep 2014;9:17-23
14. Norde WJ, Overes IM, Maas F, et al. Myeloid leukemic progenitor cells can be specifically targeted by minor histocompatibility antigen LRH-1-reactive cytotoxic T cells. Blood 2009;113:2312-23
15. Bose S, Deininger M, Gora-Tybor J, et al. The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood 1998;92:3362-7
16. Posthuma EF, Falkenburg JH, Apperley JF, et al. HLA-B8 and HLA-A3 coexpressed with HLA-B8 are associated with a reduced risk of the development of chronic myeloid leukemia. The Chronic Leukemia Working Party of the EBMT. Blood 1999;93:3863-5
17. Khosravi F, Amirzargar A, Sarafnejad A, et al. HLA class II allele and haplotype frequencies in Iranian patients with leukemia. Iran J Allergy Asthma Immunol 2007;6:137-42
18. Naugler C, Liwski R. HLA risk markers for chronic myelogenous leukemia in Eastern Canada. Leuk Lymphoma 2009;50:254-9
19. Grunebach F, Mirakaj V, Mirakaj V, et al. BCR-ABL is not an immunodominant antigen in chronic myelogenous leukemia. Cancer Res 2006;66:5892-900
20. Brauer KM, Werth D, von SK, et al. BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells. Cancer Res 2007;67:5489-97
21. Greiner J, Schmitt M. Leukemia-associated antigens as target structures for a specific immunotherapy in chronic myeloid leukemia. Eur J Haematol 2008;80:461-8
22. Smahel M. Antigens in chronic myeloid leukemia: implications for vaccine development. Cancer Immunol Immunother 2011;60:1655-68
23. Wang Q, Li M, Wang Y, et al. RNA interference targeting CML66, a novel tumor antigen, inhibits proliferation, invasion and metastasis of HeLa cells. Cancer Lett 2008;269:127-38
24. Yang J, Ikezoe T, Nishioka C, et al. Bcr-Abl activates AURKA and AURKB in chronic myeloid leukemia cells via AKT signaling. Int J Cancer 2014;134:1183-94
25. Caballero OL, Chen YT. Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci 2009;100: 2014-21
26. Rajagopalan K, Mooney SM, Parekh N, et al. A majority of the cancer/testis antigens are intrinsically disordered proteins. J Cell Biochem 2011;112:3256-67
27. Vavouri T, Lehner B. Chromatin organization in sperm may be the major functional consequence of base composition variation in the human genome. PLoS Genet 2011;7:e1002036
28. Fontana S, Alessandro R, Barranca M, et al. Comparative proteome profiling and functional analysis of chronic myelogenous leukemia cell lines. J Proteome Res 2007;6: 4330-42
29. Gannage M, Abel M, Michallet AS, et al. Ex vivo characterization of multiepitopic tumor-specific CD8 T cells in patients with chronic myeloid leukemia: implications for vaccine development and adoptive cellular immunotherapy. J Immunol 2005;174: 8210-18
30. Chen ZX, Kaeda J, Saunders S, et al. Expression patterns of WT-1 and Bcr-Abl measured by TaqMan quantitative real-time RT-PCR during follow-up of leukemia patients with the Ph chromosome. Chin Med J (Engl) 2004;117:968-71
31. Wang L, Zhu K, Zha X, et al. Evolution of T-cell clonality in a patient with Ph-negative acute lymphocytic leukemia occurring after interferon and imatinib therapy for Ph-positive chronic myeloid leukemia. J Hematol Oncol 2010;3:14
32. Warren EH, Fujii N, Akatsuka Y, et al. Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens. Blood 2010;115:3869-78
33. Brown DM. Cytolytic CD4 cells: direct mediators in infectious disease and malignancy. Cell Immunol 2010;262:89-95
34. Serody JS, Brecher ME, Dent G, et al. A method for the production of CD4+chronic myelogenous leukemia-specific allogeneic T lymphocytes. Cancer Res 1997;57:1547-53
35. Alyea EP, Soiffer RJ, Canning C, et al. Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood 1998;91:3671-80
36. Petrackova M, Lucansky V, Vonka V. Tumor protective activity of CD4+ but not of CD8+ T cells in DNA-vaccinated mice challenged with bcr-abl-transformed cells. Clin Dev Immunol 2013;2013:923107
37. ten Bosch GJ, Kessler JH, Joosten AM, et al. A BCR-ABL oncoprotein p210b2a2 fusion region sequence is recognized by HLA-DR2a restricted cytotoxic T lymphocytes and presented by HLA-DR matched cells transfected with an Ii(b2a2) construct. Blood 1999;94:1038-45
38. Yasukawa M, Ohminami H, Kaneko S, et al. CD4(+) cytotoxic T-cell clones specific for bcr-abl b3a2 fusion peptide augment colony formation by chronic myelogenous leukemia cells in a b3a2-specific and HLA-DR-restricted manner. Blood 1998;92: 3355-61
39. Gillgrass A, Ashkar A. Stimulating natural killer cells to protect against cancer: recent developments. Expert Rev Clin Immunol 2011;7:367-82
40. Demanet C, Mulder A, Deneys V, et al. Down-regulation of HLA-A and HLA-Bw6, but not HLA-Bw4, allospecificities in leukemic cells: an escape mechanism from CTL and NK attack?. Blood 2004;103: 3122-30
41. Biernacki MA, Marina O, Zhang W, et al. Efficacious immune therapy in chronic myelogenous leukemia (CML) recognizes antigens that are expressed on CML progenitor cells. Cancer Res 2010;70: 906-15
42. Yang XF, Wu CJ, McLaughlin S, et al. CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemia. Proc Natl Acad Sci USA 2001;98:7492-7
43. Greiner J, Ringhoffer M, Taniguchi M, et al. Characterization of several leukemia-associated antigens inducing humoral immune responses in acute and chronic myeloid leukemia. Int J Cancer 2003;106:224-31
44. Mumprecht S, Schurch C, Schwaller J, et al. Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression. Blood 2009;114:1528-36
45. Li Y, Lin C, Schmidt CA. New insights into antigen specific immunotherapy for chronic myeloid leukemia. Cancer Cell Int 2012;12:52-12
46. Chen S, Yang L, Chen S, et al. TCR zeta chain expression in T cells from patients with CML. Hematology (Am Soc Hematol Educ Program) 2009;14:95-100
47. Mumprecht S, Claus C, Schurch C, et al. Defective homing and impaired induction of cytotoxic T cells by BCR/ABL-expressing dendritic cells. Blood 2009;113:4681-9
48. Chen CI, Koschmieder S, Kerstiens L, et al. NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR-ABL-positive mice. Leukemia 2012;26:465-74
49. Rossignol A, Levescot A, Jacomet F, et al. Evidence for BCR-ABL-dependent dysfunctions of iNKT cells from chronic myeloid leukemia patients. Eur J Immunol 2012;42:1870-5
50. Humlova Z, Klamova H, Janatkova I, et al. Immunological profiles of patients with chronic myeloid leukaemia. I. State before the start of treatment. Folia Biol (Praha) 2006;52:47-58
51. Vonka V, Humlova Z, Klamova H, et al. Kynurenine and uric acid levels in chronic myeloid leukemia patients. Oncoimmunology 2015; In press
52. Humlova Z, Klamova H, Janatkova I, et al. Changes of immunological profiles in patients with chronic myeloid leukemia in the course of treatment. Clin Dev Immunol 2010;2010:137320
53. Steegmann JL, Moreno G, Alaez C, et al. Chronic myeloid leukemia patients resistant to or intolerant of interferon alpha and subsequently treated with imatinib show reduced immunoglobulin levels and hypogammaglobulinemia. Haematologica 2003;88:762-8
54. Nagasawa M, Mizutani S. Selective effect of imatinib on serum IgM in a patient with CML. Int J Hematol 2004;80:381-2
55. Ciarcia R, Vitiello MT, Galdiero M, et al. Imatinib treatment inhibit IL-6, IL-8, NF-KB and AP-1 production and modulate intracellular calcium in CML patients. J Cell Physiol 2012;227:2798-803
56. Reynaud D, Pietras E, Barry-Holson K, et al. IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development. Cancer Cell 2011;20:661-73
57. Pawelec G, Rehbein A, Schlotz E, et al. Cellular immune responses to autologous chronic myelogenous leukaemia cells in vitro. Cancer Immunol Immunother 1996;42:193-9
58. Rohon P, Porkka K, Mustjoki S. Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy. Eur J Haematol 2010;85:387-98
59. Christiansson L, Soderlund S, Svensson E, et al. Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1/programmed death receptor 1, and soluble CD25 in Sokal high risk chronic myeloid leukemia. PLoS One 2013;8: e55818
60. Giallongo C, Parrinello N, Tibullo D, et al. Myeloid derived suppressor cells (MDSCs) are increased and exert immunosuppressive activity together with polymorphonuclear leukocytes (PMNs) in chronic myeloid leukemia patients. PLoS One 2014;9: e101848
61. Parmigiani RB, Bettoni F, Grosso DM, et al. Antibodies against the cancer-testis antigen CTSP-1 are frequently found in prostate cancer patients and are an independent prognostic factor for biochemical-recurrence. Int J Cancer 2008;122:2385-90
62. Luetkens T, Schafhausen P, Uhlich F, et al. Expression, epigenetic regulation, and humoral immunogenicity of cancer-testis antigens in chronic myeloid leukemia. Leuk Res 2010;34:1647-55
63. Krusch M, Salih HR. Effects of BCR-ABL inhibitors on anti-tumor immunity. Curr Med Chem 2011;18:5174-84
64. De Lavallade H, Khoder A, Hart M, et al. Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling. Blood 2013;122:227-38
65. Cebo C, Da RS, Wittnebel S, et al. The decreased susceptibility of Bcr/Abl targets to NK cell-mediated lysis in response to imatinib mesylate involves modulation of NKG2D ligands, GM1 expression, and synapse formation. J Immunol 2006;176: 864-72
66. Sato N, Narita M, Takahashi M, et al. The effects of STI571 on antigen presentation of dendritic cells generated from patients with chronic myelogenous leukemia. Hematol Oncol 2003;21:67-75
67. Mohty M, Jourdan E, Mami NB, et al. Imatinib and plasmacytoid dendritic cell function in patients with chronic myeloid leukemia. Blood 2004;103:4666-8
68. Quintarelli C, Dotti G, De AB, et al. Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia. Blood 2008;112:1876-85
69. Li N, Matte-Martone C, Zheng H, et al. Memory T cells from minor histocompatibility antigen-vaccinated and virus-immune donors improve GVL and immune reconstitution. Blood 2011;118: 5965-76
70. Bornhauser M, Thiede C, Platzbecker U, et al. Prophylactic transfer of BCR-ABL-, PR1-, and WT1-reactive donor T cells after T cell-depleted allogeneic hematopoietic cell transplantation in patients with chronic myeloid leukemia. Blood 2011;117:7174-84
71. Shi H, Sun M, Liu L, et al. Chimeric antigen receptor for adoptive immunotherapy of cancer: latest research and future prospects. Mol Cancer 2014;13:219
72. Wang D, Li L, Yang H, et al. The constitutive androstane receptor is a novel therapeutic target facilitating cyclophosphamide-based treatment of hematopoietic malignancies. Blood 2013;121:329-38
73. Liu L, Sun M, Wang Z. Adoptive T-cell therapy of B-cell malignancies: conventional and physiological chimeric antigen receptors. Cancer Lett 2012;316:1-5
74. Maus MV, Grupp SA, Porter DL, et al. Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood 2014;123:2625-35
75. Lin C, Li Y. The role of peptide and DNA vaccines in myeloid leukemia immunotherapy. Cancer Cell Int 2013;13:13
76. Lucansky V, Sobotkova E, Tachezy R, et al. DNA vaccination against bcr-abl-positive cells in mice. Int J Oncol 2009;35:941-51
77. Hruskova V, Moravkova A, Babiarova K, et al. Bcr-Abl fusion sequences do not induce immune responses in mice when administered in mouse polyomavirus based virus-like particles. Int J Oncol 2009;35:1247-56
78. Petrackova M, Sobotkova E, Duskova M, et al. Isolation and properties of gene-modified mouse bcr-abl-transformed cells expressing various immunostimulatory factors. Neoplasma 2009;56:194-201
79. Petrackova M, Tachezy R, Vonka V. Properties of bcr-abl-transformed mouse 12B1 cells secreting interleukin-2 and granulocyte-macrophage colony-stimulating factor: I. Derivation, genetic stability, oncogenicity and immunogenicity. Int J Oncol 2012;40:1668-76
80. Sobotkova E, Duskova M, Tachezy R, et al. Combined chemo- and immunotherapy of tumors induced in mice by bcr-abl-transformed cells. Oncol Rep 2009;21:793-9
81. Mackiewicz J, Mackiewicz A. Gene-modified cellular vaccines: technologic aspects and clinical problems. Transplant Proc 2010;42:3287-92
82. Keenan BP, Jaffee EM. Whole cell vaccines-past progress and future strategies. Semin Oncol 2012;39:276-86
83. Smith BD, Kasamon YL, Kowalski J, et al. K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate. Clin Cancer Res 2010;16:338-47
84. Brusic A, Hainz U, Wadleigh M, et al. Detecting T-cell reactivity to whole cell vaccines: proof of concept analysis of T-cell response to K562 cell antigens in CML patients. Oncoimmunology 2012;1: 1095-103
85. Baghdadi M, Jinushi M. The impact of the TIM gene family on tumor immunity and immunosuppression. Cell Mol Immunol 2014;11:41-8